(MENAFN- Straits Research)
Market Overview
The LAMEA tulathromycin market size was valued at USD 102 million in 2025 and is projected to grow from USD 109.85 million in 2026 to reach USD 198.86 million by 2034, growing at a CAGR of 7.7% during the forecast period 2026–2034.
Tulathromycin belongs to the macrolide class of antibiotics. It is a triamilide macrolide with three charged nitrogens and a 15-membered macrolide structure (gamithromycin is also a 16-member molecule). It's made from azalide macrolides like azithromycin. It prevents bacterial protein synthesis by binding to the ribosomal 50S subunit and other macrolides. It is bacteriostatic but has bactericidal properties in vitro. Due to its positively charged molecule, it may penetrate gram-negative bacteria more quickly than other macrolide antibiotics.
Tulathromycin is used in cattle to treat BRD caused by M. haemolytica, P. multocida, and Histophilus somni (formerly Haemophilus Somnus). It is also effective in treating Mycoplasma bovis infections. When used in high-risk calves, it has also been used to prevent infections caused by these pathogens. It also treats Fusobacterium necrophorum and Porphyromonas levii-related bovine foot rot (interdigital necrobacillosis). A single dose effectively treats bovine infectious keratoconjunctivitis (Moraxella bovis).
It has been used in pigs to control and treat SRD caused by Actinobacillus pleuropneumoniae, Pneumophilus multocida, Bordetella bronchiseptica, Mycoplasma hyopneumoniae, and Haemophilus parasuis. Tulathromycin has been used to treat pulmonary abscesses in foals (off-label use).
Download a Free Sample To learn more about this report,
Market Dynamics
Market Drivers
An Increase in Respiratory Diseases Will Increase the Demand for Tulathromycin
Bovine Respiratory Diseases (BRD) are a major concern in young and old animals. Every year, it affects 20-25% of calves, causing developmental delays for 10% of them and a death rate of up to 6%. Similarly, the increasing Swine Respiratory Diseases (SRD) in pigs can be around 20%, with a risk of sequelae of up to 40% of impacted animals and a death rate of up to 20%.
Previously, BRD and SRD had a significant monetary impact on farmers due to reduced animal development, finding and treatment expenses, mortality, and expenses associated with additional work.
Market Restraints
Generic Tulathromycin Will Limit Market Growth
The FDA in the United States approved two generic tulathromycin injections in late 2021 to treat and control specific illnesses in both cows and pigs. BRD is treated with both Macrosyn and Increxxa. Furthermore, it is used to treat SRD in pigs caused by Actinobacillus pleuropneumonia, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae.
Tulathromycin is present in Macrosyn and Increxxa in the same concentration and dose structure as the supported drug item, Draxxin. The active ingredient (tulathromycin) in Macrosyn and Increxxa is the same as in the approved brand name drug product, Draxxin, first approved in 2005. Furthermore, the FDA determined that Macrosyn and Increxxa do not contain any inactive ingredients that could interfere with the active ingredient's bioavailability. In the coming years, the general interest in tulathromycin will likely be hampered by these two conventional medications.
Tulathromycin is a critical antibacterial in human medicine, and it should be handled with caution. As a result, Macrosyn and Increxxa, like Draxxin, are only available by prescription since a veterinarian's knowledge is required to identify whether tulathromycin is appropriate medication and to guide its wise use in order; to reduce the spread of antimicrobial resistance. Furthermore, tulathromycin is only approved for a single dose. The FDA does not expect these generic approvals to increase overall tulathromycin use; rather, they will provide veterinarians with options when prescribing a tulathromycin product.
Segmental Analysis
The market for tulathromycin can be broken down into three categories based on type: greater than 99.0%, 98.0% to less than or equal to 99.0%, and 98% or less. The sub-segment of the market for tulathromycin is anticipated to hold the most significant market share throughout the projected period. Demand has increased across various industries, including Materials and Chemicals, for industrial valves of the highest possible quality. The current demand for tulathromycin is partly driven by the need to reduce the possibility of contamination. It is anticipated that the growing worry regarding the market and industry will drive the market for tulathromycin in the materials and chemicals sector.
Cattle, pigs, and other animals are the categories that make up this segment of the market for tulathromycin. Application valves for tulathromycin are among the most fundamental and essential components of the advanced technological world that we live in today. In the market for tulathromycin, it is anticipated that this market category will occupy the most significant market share.
Request Customization to receive a tailored report.
Speak to an Analyst to discuss market opportunities.
Regional Analysis
The LAMEA Tulathromycin market is divided into Brazil, Argentina, Chile, Saudi Arabia, United Arab Emirates, South Africa, Iran, Turkey, Morocco, Nigeria & Rest of LAMEA, based on country.
Brazil, Mexico, Argentina, and Colombia have the largest economies in Latin America and the highest cattle and pig populations. Brazil now accounts for more than half of the regional cattle population, owing to the rising demand for dairy and meat products. The number of bovines in Brazil has expanded dramatically in recent years, and this estimate reflects the fact that more meat is being traded each year. The prevalence of BRD is significant, which expands the LAMEA tulathromycin market in these regions.
List of Key and Emerging Players in LAMEA Tulathromycin Market
Zhejiang Genebest Pharmaceutical
AVF Chemical Industrial
Rochem
Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd
Hubei Honch Pharmaceutical Co.,ltd
Hubei Weideli Chemical Science and Technology Co., Ltd
Zoetis
Wuhan Kemick Biomedical Technology Co., Ltd
Jiangsu Lingyun Pharmaceutical
Amicogen (China) Biopharm
Livzon New North River Pharmaceutical
Key Industry Developments
May 2026: Huvepharma expanded the availability of its tulathromycin injectable veterinary portfolio across Middle Eastern and African markets through new regional distribution partnerships, strengthening access to long-acting respiratory disease treatments for livestock.
March 2026: Virbac expanded its livestock pharmaceutical portfolio in Latin America with additional commercialization initiatives for tulathromycin-based injectable antibiotics used in cattle and swine respiratory disease management.
January 2026: Ceva Santé Animale strengthened its veterinary business in the Middle East through expanded technical support and distribution agreements for long-acting antimicrobial products, including tulathromycin formulations for food-producing animals.
October 2025: Zoetis expanded veterinary education and antimicrobial stewardship programs across Latin America to support the appropriate use of long-acting injectable antibiotics, including tulathromycin, in cattle production.
Report Scope
Comments
No comment